Manage childhood myopia
with data.
Catch myopia progression early and intervene at the right time. Refraction and axial length tracking, BHVI prognosis and treatment comparison — all on one platform.
No installation. Runs in your browser. Already have an account?
Projected myopia patients by 2050 — half the world's population
Expected slowdown in progression with low-dose atropine (0.05%)
The most critical onset window for intervention
Why myopia can't wait
Myopia is blurred distance vision caused by an eyeball that is longer than normal. Myopia that begins in childhood progresses rapidly until adolescence.
- High myopia (≤ −6 D) multiplies the risk of retinal detachment and glaucoma.
- If left uncontrolled, it can progress to −8 D, even −10 D.
- Myopia that starts at an early age progresses for longer and faster.
- Evidence-based treatments can slow progression by 30–60%.
Built for clinicians
Every exam is analyzed with historical comparison; prognosis and treatment decisions are tracked on a single screen.
Ayşe Kaya· age 9
Last measurement · May 14, 2026
Refraction & biometry tracking
Record SPH, CYL, AX and axial length measurements; the progression rate updates automatically with every new entry.
Prognosis with the BHVI methodology
Estimated refraction at ages 18 and 21, high-myopia likelihood and progression category.
Treatment comparison
Compare the efficacy of atropine, orthokeratology, MiSight and DIMS side by side on the prognosis chart.
KVKK-compliant secure data
All records are encrypted in transit and processed under KVKK, Türkiye's GDPR-equivalent data-protection law; only the authorized clinician and the relevant patient/parent can access them.
A myopia control program in four steps
Create an account
Register for free as a clinician or patient/parent; your first prognosis is ready in five minutes.
Enter measurements
Record SPH, CYL, AX and axial length values at each exam.
See the prognosis
Age 18–21 estimates, progression rate and risk category are computed automatically with the BHVI methodology.
Track treatment
Compare the effects of atropine, Ortho-K, MiSight and DIMS on a chart and follow the course.
Factors that accelerate myopia
Parental myopia
Two myopic parents raise a child's risk roughly sixfold.
Screens & near work
More than 4 hours of sustained near work a day — screens, tablets, books — is associated with faster progression.
Insufficient outdoor time
Less than 2 hours outdoors per day markedly increases myopia risk.
Early onset age
Myopia starting at age 6–8 carries a risk of becoming high myopia by age 18.
Clinician and parent, on the same chart
The clinician measures and decides; the parent follows along on the same chart. Reports are shared with a single link.
If you're a clinician
- Record measurements in seconds during the exam
- Track the progression rate and BHVI prognosis automatically
- Share the report with the parent via a single link
If you're a parent
- See your child's measurements and progression chart
- Access the report and treatment plan your clinician shares
- Keep up with appointments and check-ups
Frequently asked
What is MiyoLab?
MiyoLab is a clinical management platform built to scientifically track childhood myopia (nearsightedness). It offers measurement tracking, prognosis with the BHVI methodology and treatment comparison for clinicians.
How is myopia tracked in children?
The child's periodic refraction (SPH/CYL/AX) and axial length measurements are recorded on the platform; the system automatically computes the progression rate and BHVI prognosis. Treatment decisions are thus tracked within a structured myopia control program.
Is MiyoLab free?
Yes, creating an account and using the tracking features is free. You can register as a clinician or a patient/parent; no installation required, it runs in your browser.
What is the BHVI prognosis?
The Brien Holden Vision Institute (BHVI) methodology estimates the child's refraction at ages 18 and 21 and the likelihood of high myopia, based on current measurements.
Which treatments can I compare?
You can compare, side by side on a chart, the effect on progression of evidence-based treatments such as low-dose atropine, orthokeratology (Ortho-K), MiSight contact lenses and DIMS spectacle lenses.
Is my data safe?
All data is transmitted over an encrypted connection and processed under KVKK, Türkiye's data-protection law. Only the authorized clinician and the relevant patient/parent can access patient records.
Act before myopia progresses
Create a free account — clinician or patient/parent. Your first prognosis is ready in five minutes.